Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Morphic Holding stock

Own Morphic Holding stock in just a few minutes.

Morphic Holding, Inc is a biotechnology business based in the US. Morphic Holding shares (MORF) are listed on the NASDAQ and all prices are listed in US Dollars. Morphic Holding employs 89 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Morphic Holding

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MORF – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Morphic Holding share price

Use our graph to track the performance of MORF stocks over time.

Morphic Holding shares at a glance

Information last updated 2021-04-21.
52-week range$12.25 - $75.95
50-day moving average $62.58
200-day moving average $39.68
Wall St. target price$102.75
PE ratio 6.9814
Dividend yield N/A (0%)
Earnings per share (TTM) $-17.63

Buy Morphic Holding shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Morphic Holding stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Morphic Holding under- or over-valued?

Valuing Morphic Holding stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Morphic Holding's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Morphic Holding's P/E ratio

Morphic Holding's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Morphic Holding shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Morphic Holding financials

Revenue TTM $44.9 million
Gross profit TTM $-28,685,000
Return on assets TTM -12.04%
Return on equity TTM -31.46%
Profit margin -100.12%
Book value $4.53
Market capitalisation $2 billion

TTM: trailing 12 months

Shorting Morphic Holding shares

There are currently 604,677 Morphic Holding shares held short by investors – that's known as Morphic Holding's "short interest". This figure is 29.3% down from 854,867 last month.

There are a few different ways that this level of interest in shorting Morphic Holding shares can be evaluated.

Morphic Holding's "short interest ratio" (SIR)

Morphic Holding's "short interest ratio" (SIR) is the quantity of Morphic Holding shares currently shorted divided by the average quantity of Morphic Holding shares traded daily (recently around 944807.8125). Morphic Holding's SIR currently stands at 0.64. In other words for every 100,000 Morphic Holding shares traded daily on the market, roughly 640 shares are currently held short.

However Morphic Holding's short interest can also be evaluated against the total number of Morphic Holding shares, or, against the total number of tradable Morphic Holding shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Morphic Holding's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Morphic Holding shares in existence, roughly 20 shares are currently held short) or 0.0355% of the tradable shares (for every 100,000 tradable Morphic Holding shares, roughly 36 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Morphic Holding.

Find out more about how you can short Morphic Holding stock.

Morphic Holding share dividends

We're not expecting Morphic Holding to pay a dividend over the next 12 months.

Morphic Holding overview

Morphic Holding, Inc. , a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß1 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Morphic Holding is owned by insiders or institutions?
Currently 30.922% of Morphic Holding shares are held by insiders and 58.508% by institutions.
How many people work for Morphic Holding?
Latest data suggests 89 work at Morphic Holding.
When does the fiscal year end for Morphic Holding?
Morphic Holding's fiscal year ends in December.
Where is Morphic Holding based?
Morphic Holding's address is: 35 Gatehouse Drive, A2, Waltham, MA, United States, 02451
What is Morphic Holding's ISIN number?
Morphic Holding's international securities identification number is: US61775R1059
What is Morphic Holding's CUSIP number?
Morphic Holding's Committee on Uniform Securities Identification Procedures number is: 61775R105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site